Literature DB >> 6415230

Immunological properties of monoclonal antibodies specific for meningococcal polysaccharides: the protective capacity of IgM antibodies specific for polysaccharide group B.

C Moreno, J Hewitt, K Hastings, D Brown.   

Abstract

Two IgM monoclonal antibodies, MB32 and MB34 specific for meningococcal polysaccharide group B have been raised. Both were detectable by radioimmunoassay and agglutination, but only MB34 was effective in counter immunoelectrophoresis and complement fixation. MB34 was also far more potent than MB32 when tested for passive protection of mice infected with either Neisseria meningitidis group B or Escherichia coli K1. These data demonstrate that group B-specific antibodies do play a protective role in mice infected with these bacteria.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6415230     DOI: 10.1099/00221287-129-8-2451

Source DB:  PubMed          Journal:  J Gen Microbiol        ISSN: 0022-1287


  18 in total

Review 1.  New aspects of vaccine development.

Authors:  F Y Liew
Journal:  Clin Exp Immunol       Date:  1985-11       Impact factor: 4.330

2.  Specificity of the immune response to the group B polysaccharide of Neisseria meningitidis.

Authors:  M R Lifely; J Esdaile
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

3.  Thymic-dependence and immune memory in mice vaccinated with meningococcal polysaccharide group B complexed to outer membrane protein.

Authors:  C Moreno; J Esdaile; M R Lifely
Journal:  Immunology       Date:  1986-03       Impact factor: 7.397

Review 4.  Monoclonal antibodies to polysialic acid reveal epitope sharing between invasive pathogenic bacteria, differentiating cells and tumor cells.

Authors:  D Bitter-Suermann; J Roth
Journal:  Immunol Res       Date:  1987       Impact factor: 2.829

5.  Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis.

Authors:  Maija Toropainen; Leena Saarinen; Elisabeth Wedege; Karin Bolstad; Terje E Michaelsen; Audun Aase; Helena Käyhty
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

6.  Monoclonal antibodies: technology and application to gram-negative infections.

Authors:  L S Young
Journal:  Infection       Date:  1985       Impact factor: 3.553

7.  Molecular analysis of anti-N-propionyl Neisseria meningitidis group B polysaccharide monoclonal antibodies.

Authors:  Gregory R Moe; Apurva Dave; Dan M Granoff
Journal:  Mol Immunol       Date:  2005-09-02       Impact factor: 4.407

Review 8.  Monoclonal antibodies: technology and application to gram-negative infections.

Authors:  L S Young
Journal:  Infection       Date:  1984 Jul-Aug       Impact factor: 3.553

9.  Production of polyclonal and monoclonal antibodies against group A, B, and C capsular polysaccharides of Neisseria meningitidis and preparation of latex reagents.

Authors:  F Nato; J C Mazie; J M Fournier; B Slizewicz; N Sagot; M Guibourdenche; D Postic; J Y Riou
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

10.  Antibodies to O-antigen of lipopolysaccharide are protective against neonatal infection with Escherichia coli K1.

Authors:  G Pluschke; M Achtman
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.